Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: corbuspharma.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/30/2024 | $85.00 | Outperform | Wedbush |
7/22/2024 | $80.00 | Buy | H.C. Wainwright |
6/26/2024 | $85.00 | Buy | B. Riley Securities |
6/3/2024 | $60.00 → $80.00 | Outperform | Oppenheimer |
5/13/2024 | $77.00 | Outperform | RBC Capital Mkts |
3/6/2024 | $4.00 → $46.00 | Hold → Buy | Jefferies |
Wedbush initiated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $85.00
H.C. Wainwright resumed coverage of Corbus Pharma with a rating of Buy and set a new price target of $80.00
B. Riley Securities initiated coverage of Corbus Pharma with a rating of Buy and set a new price target of $85.00
Oppenheimer reiterated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $80.00 from $60.00 previously
RBC Capital Mkts initiated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $77.00
Jefferies upgraded Corbus Pharma from Hold to Buy and set a new price target of $46.00 from $4.00 previously
Oppenheimer resumed coverage of Corbus Pharmaceuticals with a rating of Hold
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the Corbus Board of Directors. "We are delighted to welcome someone of Winston's stature and expertise to our Board and we look forward to his insights and guidance." "Winston brings an e
Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial cancer or cervical cancerCRB-701 Phase 1 dose escalation underway in USA and Europe for patients with metastatic urothelial cancer and other nectin-4 enriched tumors and is on schedule for completion in Q4 2024Cash runway extended through Q3 2027 with $147 million of cash & investments at June 30, 2024 NORWOOD, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today provided a corporate update and reported financial results for the quarter ended June 30, 2024. "We c
NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in two investor conferences during the month of August. Dr. Cohen will provide a corporate update and participate in one-on-one investor meetings at the following events. BTIG Virtual Biotechnology Conference Date: August 5-6, 2024Format: Invitation only, one-on-one investor meetingsNote: Investors interested in attending and meeting with management should contact their BTIG representatives. Wedbush PacGrow Healthcare Conference Date: August 13-14, 2024Format: Invit
An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses ≥ 1.2mg/KgNo dose limiting toxicities (DLTs) have been observed to date in doses up to and including 4.5 mg/Kg (cohort 7)Three cases of skin rash (including one grade 3) and one case of grade 1 neuropathy seen to date; all were resolvedEarly PK data demonstrate consistently lower levels of free MMAE than enfortumab vedotin across all doses in study including 4.5 mg/Kg NORWOOD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdin
NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the 45th Annual Goldman Sachs Global Healthcare Conference to be held June 10-13, 2024 in Miami Beach, FL. 45th Annual Goldman Sachs Global Healthcare Conference Format: Presentation and one-on-one investor meetingsPresentation Date: Wednesday, June 12, 2024Presentation Time: 2:40 p.m. ETWebcast: Click Here About Corbus Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a dive
NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company") announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate and will be presented as a poster [#296] on June 1, 2024 from 9:00 AM -12:00 PM by Dr. Jian Zhang, Fudan University Shanghai Cancer Center. The poster will update data contained in the abstract [
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2024 RBC Capital Markets Global Healthcare Conference to be held May 14-15, 2024 in New York, NY. 2024 RBC Capital Markets Global Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsPresentation Date: Tuesday, May 14, 2024Presentation Time: 9:30 a.m. ETWebcast: Click Here About Corbus Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio and is
Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 Appointed Dr. Dominic Smethurst as Chief Medical Officer NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2024. "During the first quarter of 2024, we continued to make significant progress in advancing our pipeline toward meaningful milestones led by the dosing of the first patie
NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the BTIG Obesity Health Forum, to be held virtually on May 8, 2024. Details of the panel discussion are as follow: BTIG Obesity Health ForumPanel Title: CB1 Axis Therapies for ObesityDate: Wednesday, May 8, 2024Presentation Time: 3:00 p.m. ET For further information about participating in the virtual forum, contact your BTIG representative. About CorbusCorbus Pharmaceuticals Holdings, Inc. is a precision oncology company with
NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that an abstract providing updated data from the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology annual meeting, to be held May 31-June 4, 2024 in Chicago, IL. CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4 with a third generation, site-specific cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. En
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
10-Q - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
144 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
S-8 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the Corbus Board of Directors. "We are delighted to welcome someone of Winston's stature and expertise to our Board and we look forward to his insights and guidance." "Winston brings an e
NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company's h
NORWOOD, Mass., March 6, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors. "Dr. Ben is a distinguished oncology researcher and pharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition to our Board," said Alan Holmer, Chairman of the Board of Directors of Corbus. "Our recent license agreement for CRB-701 has helped cement our position as a precision o
NORWOOD, Mass., Sept. 26, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an immunology company, today announced the appointment of Anne Altmeyer, PhD, MBA, MPH to its board of directors. "Anne is a dynamic leader with a proven track record of advancing R&D programs and creating corporate value through successful business development transactions," said Alan Holmer, Chairman of the Board of Directors of Corbus. "Her corporate development expertise and oncology R&D experience will be invaluable to Corbus as we advance and
NEW YORK and LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LBT4) systems are implicated, today announced the appointment of Rachelle Jacques as President and Chief Executive Officer of Akari Therapeutics. Ms. Jacques will also join the company's Board of Directors. Her appointment begins at the end of March 2022. Outgoing Chief Executive Officer, Clive Richardson, will continue to serve the Company, supporting Rachelle to accelerate business development and ensuring a smooth transition."
NORWOOD, Mass., Dec. 7, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company") today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company's mission of connecting innovation to purpose. Dr. Brake will build upon Corbus' commitment to immuno-oncology and joins the Company following the recent acquisition of monoclonal antibodies that inhibit TGFβ activation. Dr. Brake most recently served at Takeda Pharmaceuticals where she held multiple leadership roles across the R&D continuum, inc
LEXINGTON, Mass. and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors. Ms. Jacques, who will serve on the Board's Audit Committee, has more than 25 years of industry experience in strategic, cross-functional executive roles spanning finance, business operations, manufacturing, and commercial. She has led successful launches of several rare disease therapies including the recent approval of a Regenerative Medicine Advanced Therapy (RMAT)-designated product, one of only three since the p
HC Wainwright & Co. analyst Andrew Fein reinstates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and announces $80 price target.
GAINERS: Green Growth Brands (OTC:GGBXF) shares closed up 9900.00% at $0.0001 Rocky Mountain High (OTC:RMHB) shares closed up 33.33% at $0.02 SOL Glb Inv (OTC:SOLCF) shares closed up 19.57% at $0.05 Affinor Growers (OTC:RSSFF) shares closed up 19.12% at $0.08 Pharmadrug (OTC:LMLLF) shares closed up 18.52% at $0.02 1933 Industries (OTC:TGIFF) shares closed up 8.23% at $0.01 Cansortium (OTC:CNTMF) shares closed up 7.14% at $0.15 CV Sciences (OTC:CVSI) shares closed up 7.12% at $0.06 CLS Holdings USA (OTC:CLSH) shares closed up 6.26% at $0.04 Cipher Pharmaceuticals (OTC:CPHRF) shares closed up 5.67% at $6.43 Body and Mind (OTC:BMMJ) shares closed up 5.40% at $0.03 OrganiGram Holdings (NASDAQ:O
GeneDx Holdings Corp. (NASDAQ:WGS) has made the biggest gains on the Russell 2000 Index in 2024 as the biotechnology company moves toward more comprehensive genetic testing. The Maryland-based company’s shares have soared 1,101% so far this year as of midday Thursday, according to Tradingview. Goldman Sachs analyst Matthew Sykes attributes much of GeneDX’s positive momentum to shifting its testing. The company went from panel-based tests, which look for variants in more than one gene, to exome/genome testing, which analyzes the bulk of a person’s DNA to find genetic variations. Also Read: GeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 Guidance “We remain o
GAINERS: Zelira Therapeutics (OTC:ZLDAF) shares closed up 69.95% at $0.48 Global Hemp Group (OTC:GBHPF) shares closed up 40.00% at $0.03 CordovaCann (OTC:LVRLF) shares closed up 29.03% at $0.04 Elixinol Wellness (OTC:ELLXF) shares closed up 25.00% at $0.00 Eastside Distilling (NASDAQ:EAST) shares closed up 23.57% at $1.20 Body and Mind (OTC:BMMJ) shares closed up 15.70% at $0.04 Pharmadrug (OTC:LMLLF) shares closed up 15.25% at $0.01 1933 Industries (OTC:TGIFF) shares closed up 14.86% at $0.01 Maple Leaf Green World (OTC:MGWFF) shares closed up 10.69% at $0.03 Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed up 10.42% at $58.92 Rocky Mountain High (OTC:RMHB) shares closed up 8.33% at $0.0
GAINERS: Australis Capital (OTC:AUSAF) shares closed up 9900.00% at $0.0001 Cara Therapeutics (NASDAQ:CARA) shares closed up 25.84% at $0.37 4Front Ventures (OTC:FFNTF) shares closed up 23.42% at $0.10 Cannabix Technologies (OTC:BLOZF) shares closed up 15.92% at $0.43 Global Compliance (OTC:FUAPF) shares closed up 12.75% at $0.01 22nd Century Group (NASDAQ:XXII) shares closed up 11.92% at $0.79 Curaleaf Holdings (OTC:CURLF) shares closed up 9.71% at $4.18 SOL Glb Inv (OTC:SOLCF) shares closed up 9.05% at $0.04 OrganiGram Holdings (NASDAQ:OGI) shares closed up 7.59% at $1.70 RIV Capital (OTC:CNPOF) shares closed up 7.14% at $0.10 GrowGeneration (NASDAQ:GRWG) shares closed up 6.82% at $2.35 A
Oppenheimer analyst Jeff Jones reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and maintains $80 price target.
GAINERS: Affinor Growers (OTC:RSSFF) shares closed up 76.74% at $0.17 Global Compliance (OTC:FUAPF) shares closed up 39.00% at $0.01 CNBX Pharmaceuticals (OTC:CNBX) shares closed up 33.33% at $0.01 Elixinol Wellness (OTC:ELLXF) shares closed up 32.50% at $0.00 SOL Glb Inv (OTC:SOLCF) shares closed up 18.50% at $0.05 Target Group (OTC:CBDY) shares closed up 10.90% at $0.00 Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed up 9.17% at $49.40 Auxly Cannabis Group (OTC:CBWTF) shares closed up 7.14% at $0.02 Cara Therapeutics (NASDAQ:CARA) shares closed up 7.02% at $0.26 Cannabix Technologies (OTC:BLOZF) shares closed up 4.24% at $0.35 Cansortium (OTC:CNTMF) shares closed up 3.85% at $0.14 CLS
GAINERS: 1933 Industries (OTC:TGIFF) shares closed up 25.00% at $0.01 Target Group (OTC:CBDY) shares closed up 24.80% at $0.00 4Front Ventures (OTC:FFNTF) shares closed up 14.67% at $0.09 SOL Glb Inv (OTC:SOLCF) shares closed up 11.42% at $0.04 Auxly Cannabis Group (OTC:CBWTF) shares closed up 11.41% at $0.02 Pharmadrug (OTC:LMLLF) shares closed up 8.42% at $0.02 iAnthus Capital Hldgs (OTC:ITHUF) shares closed up 7.76% at $0.02 RIV Capital (OTC:CNPOF) shares closed up 6.73% at $0.11 C21 Investments (OTC:CXXIF) shares closed up 5.00% at $0.27 CV Sciences (OTC:CVSI) shares closed up 4.09% at $0.06 EnWave (OTC:NWVCF) shares closed up 3.70% at $0.17 Corbus Pharmaceuticals (NASDAQ:CRBP) shares c
B. Riley Securities analyst Kalpit Patel initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and announces Price Target of $85.